As a specific Bcl-2 inhibitor, venetoclax effectively induces apoptosis in vitro in cancer cells that overexpress Bcl-2.[85] In a time- and concentration-dependent way, Yuan et al found that venetoclax and HHT worked in concert to suppress AML growth, lower mitochondrial membrane potential, and accelerate AML cell death. The gene discussed is BCL2; the disease is cancer.